Potential of Peroxisome Proliferator-Activated Receptor Gamma Antagonist Compounds as Therapeutic Agents for a Wide Range of Cancer Types

Table 1

Mean IC₅₀ values (𝜇M) for the PPARγ ligands.

Cell lines	Pioglitazone	T0070907	GW9662
Colon
Moser^#	26.5±2.6	15.9±1.0	20.1±0.3
HT29§	53.0±4.7	11.2±0.0	14.1±0.5
LS174T^#	38.7±7.4	7.8±1.9	9.5±0.5
HCT-15§	53.1±2.5	13.0±0.5	19.0±0.8
RCC
A498^#	38.9±4.9	24.3±0.7	29.1±0.3
ClearCa-2§	56.4±3.1	20.8±1.9	21.5±0.7
Breast
ZR75-30§	77.9±7.0	3.9±0.3	10.6±0.9
MCF7§	54.8±3.9	10.2±1.9	16.6±2.4
MDA-MB-231§	78.7±3.5	20.1±1.1	26.8±1.0
MM
CAG^*	62.4±9.9	12.2±1.2	13.8±0.1
KMS12-BM§	33.2±5.1	3.2±0.6	11.8±1.6
KMS12-PE§	56.4±1.5	4.3±0.3	9.5±0.9
OPM6§	48.9±1.8	4.1±0.3	11.5±0.1
U266B1§	56.6±1.3	9.9±0.2	29.7±1.5
NHL
Ramos§	66.5±7.4	12.7±0.7	15.1±0.1
SU-DHL6§	53.1±1.4	11.8±0.4	14.8±0.3

Mean IC₅₀ values from replicate experiments with this panel of cells for each of the three PPARγ ligands are shown above, expressed in 𝜇M±SEM. Cell lines are grouped according to cancer type. IC₅₀ values from each cell line were compared by single factor ANOVA analysis, with all lines showing significant differences as indicated: ^§𝑃<.0001;^∗𝑃<.005;^#𝑃<.04.